Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

Rhea-AI Summary

Apellis Pharmaceuticals, a leader in complement medicine, announced its participation in two upcoming March investor conferences:

• Cowen 43rd Annual Healthcare Conference: Fireside chat on March 8, 2023, at 9:10 a.m. ET.
• Oppenheimer’s 33rd Annual Healthcare Conference: Virtual fireside chat on March 13, 2023, at 3:20 p.m. ET.

Both events will have live webcasts available on the company’s website, with replays accessible for 90 days. Apellis focuses on innovative therapies aimed at complex diseases, boasting two approved medications for targeting complement C3. For more details, visit apellis.com.

WALTHAM, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will participate in the following March investor conferences:

• Cowen 43rd Annual Healthcare Conference: Fireside chat on Wednesday, March 8, 2023, at 9:10 a.m. ET.
• Oppenheimer’s 33rd Annual Healthcare Conference: Virtual fireside chat on Monday, March 13, 2023, at 3:20 p.m. ET.

Each conference event will be available via a live webcast from the “Events and Presentations” page of the “Investors and Media” section of the company’s website. A replay of the webcasts will be available for 90 days following the event.

About Apellis
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that combines courageous science and compassion to develop life-changing therapies for some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in 15 years and now have two approved medicines targeting C3. These include the first and only therapy for geographic atrophy, a leading cause of blindness around the world. With nearly a dozen clinical and pre-clinical programs underway, we believe we have only begun to unlock the potential of targeting C3 across many serious diseases. For more information, please visit http://apellis.com or follow us on Twitter and LinkedIn.

Investor Contact: 
Meredith Kaya 
meredith.kaya@apellis.com
617.599.8178

FAQ

What are the dates and times for the investor conferences Apellis Pharmaceuticals is attending in March 2023?

Apellis Pharmaceuticals will participate in the Cowen 43rd Annual Healthcare Conference on March 8, 2023, at 9:10 a.m. ET, and the Oppenheimer’s 33rd Annual Healthcare Conference on March 13, 2023, at 3:20 p.m. ET.

How can I watch the Apellis Pharmaceuticals investor conference webcasts?

The webcasts for the Apellis Pharmaceuticals investor conferences will be available via the 'Events and Presentations' page on their website.

What is APLS's focus in the biopharmaceutical industry?

APLS, or Apellis Pharmaceuticals, focuses on developing therapies targeting complement C3 for serious diseases, including the first treatment for geographic atrophy.

Where can I find more information about Apellis Pharmaceuticals?

For more information, visit Apellis Pharmaceuticals' official website at apellis.com.